Cayuga Biotech
PrivateLast Round
Seed
Dec 11, 2025
Est. Valuation
$3.13M
Total Funding Raised
$8.74M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Cayuga Biotech operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Seed round in December 2025.
Cayuga Biotech is a biotechnology company that develops novel therapeutics to address life-threatening hemorrhage and bleeding disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Advanced Materials
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cayuga Biotech Comparables
Compare Cayuga Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Haima Therapeutics | 87% | |
| RxMP Therapeutics, Inc. | 86% | |
| Coagulant Therapeutics Corporation | 79% |
For institutional investors. Book with your work email.
Cayuga Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Seed | Dec 11, 2025 | ||||
| Accelerator | Jun 2, 2020 | ||||
| Accelerator | May 1, 2020 | ||||
| Grant | Oct 16, 2019 |
For institutional investors. Book with your work email.
Cayuga Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| TBD Angels | Seed |
| Defense Health Agency | Grant |
| Wharton Alumni Angels | Seed |
| Walnut Ventures | Seed |
| IndieBio | Accelerator |
| New York Ventures | Seed |
| Purchase Capital | Seed |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 217% MoM.
- Dec 11, 2025
$5M round led by Wharton Alumni Angels
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 10, 2026
Cayuga Biotech presents initial results from its first-in-human Phase 1 study of CAY001 at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, Louisiana, on Dec 12th–15th '26.
- attends_eventNov 10, 2026
Cayuga Biotech plans to present initial Phase 1 results of CAY001 at the 2026 ASH Annual Meeting, taking place in Louisiana on Dec 12th–15th '26.
For institutional investors. Book with your work email.
Cayuga Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cayuga Biotech's valuation, stock price, and market status.
Is Cayuga Biotech a public or private company?
Cayuga Biotech is a private company.
What is the current stock price of Cayuga Biotech?
Cayuga Biotech is a private company, so its shares have no public market price. Caplight tracks Cayuga Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cayuga Biotech worth (valuation)?
Cayuga Biotech's valuation is estimated at $3.1M based on funding round data.
Can I buy Cayuga Biotech stock?
Cayuga Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cayuga Biotech's last funding round?
Cayuga Biotech's most recent funding round was Seed on December 11, 2025.
Who are the main investors in Cayuga Biotech?
Key investors in Cayuga Biotech include Wharton Alumni Angels, SOSV.
Will Cayuga Biotech IPO soon?
No public IPO plans have been announced for Cayuga Biotech.
How can I track Cayuga Biotech secondary market activity?
Caplight tracks bids, offers, and trades in Cayuga Biotech's shares on secondary markets.